The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance

• Conditions: Ovarian Cancer
• Interventions: Other: Biopsy

• Registration Number: NCT03846856
• Lead Sponsor: Hillel Yaffe Medical Center

Brief Summary

The aim of this study is to evaluate the insulin-like growth factor (IGF) axis involvement in the immune tumor microenvironment in ovarian cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-02-18
• Study First Submitted QC: 2019-02-18
• Study First Posted: 2019-02-20
• Status Verified: 2019-04
• Study Start: 2019-04
• Last Update Submitted: 2019-04-03
• Last Update Posted: 2019-04-04
• Primary Completion: 2021-03
• Study Completion: 2021-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

• Women diagnosed with epithelium ovarian cancer who have undergone surgery

Exclusion Criteria

• Pregnant women

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Ovarian cancer patients	Biopsy	Biopsy will be taken from ovarian cancer patients and sent to laboratory for analysis

Primary Outcome Measures

Name	Time	Method
Involvement of IGF Axis in Ovarian Cancer	Two years	Ovarian cancer specimens taken during surgical procedures will be evaluated and analyzed by flow cytometry assays to determine the involvement of the IGF axis in the immune tumor microenvironment in ovarian cancer

Trial Locations

Locations (1)

Hillel Yaffe Medical Center; 🇮🇱 Hadera, Israel